• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Equillium Inc.

    2/14/22 11:57:43 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    SC 13G 1 tm226449d5_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*

     

    Equillium Inc. 

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value 

    (Title of Class of Securities) 

     

    29446K106 

    (CUSIP Number)

     

    Laura Tse

    3000 Sand Hill Road, Building 2, Suite 110

    Menlo Park, CA 94025, USA

    650-233-0688

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 31, 2021 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    þ Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 29446K106 13G Page 2 of 5 Pages

     

    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Decheng Capital Management III (Cayman), LLC

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
    3.   SEC USE ONLY
     
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    4,447,308
      6.   SHARED VOTING POWER
     
    4,447,308
      7.   SOLE DISPOSITIVE POWER
     
    4,447,308
      8.   SHARED DISPOSITIVE POWER
     
    4,447,308

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,447,308

    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨
    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.13%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IA 

     

     

     

     

    CUSIP No. 29446K106 13G Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer
    Equillium Inc.

     

      (b) Address of Issuer’s Principal Executive Offices
    2223 Avenida De La Playa, Suite 105, La Jolla, California 92037, USA

     

    Item 2.

     

      (a) Name of Person Filing
    Laura Tse
         
      (b) Address of the Principal Office or, if none, residence
    3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025, USA
         
      (c) Citizenship
    U.S.
         
      (d) Title of Class of Securities
    Common Stock, $0.0001 Par Value
         
      (e) CUSIP Number
    29446K106

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) þ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    CUSIP No. 29446K106 13G Page 4 of 5 Pages

     

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:  4,447,308
             
      (b)   Percent of class:  15.13%
             
      (c)   Number of shares as to which the person has:  
             
          (i) Sole power to vote or to direct the vote 4,447,308
             
          (ii) Shared power to vote or to direct the vote 4,708,288
             
          (iii) Sole power to dispose or to direct the disposition of 4,447,308
             
          (iv) Shared power to dispose or to direct the disposition of 4,447,308

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

    None/Not Applicable

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    None/Not Applicable

     

    Item 8.  Identification and Classification of Members of the Group.

     

    None/Not Applicable

     

    Item 9.  Notice of Dissolution of Group.

     

    None/Not Applicable

     

     

     

     

    CUSIP No. 29446K106 13G Page 5 of 5 Pages

     

    Item 10.  Certification.

     

      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
           
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      2/14/2022 
      Date
       
      /s/ Laura Tse   
      Signature
       
      Chief Compliance Officer   
      Name/Title

     

     

    Get the next $EQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    5/28/2026$6.00Market Perform → Outperform
    Leerink Partners
    4/23/2026$7.00Outperform
    Oppenheimer
    4/16/2026$6.00Buy
    B. Riley Securities
    4/14/2026$6.00Strong Buy
    Raymond James
    4/7/2026$10.00Overweight
    Cantor Fitzgerald
    3/13/2026$12.00Buy
    Roth Capital
    2/25/2026$5.00Buy
    Stifel
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Tom Penny sold $191,750 worth of shares (65,000 units at $2.95) as part of a pre-agreed trading plan and exercised 65,000 shares at a strike of $0.79 (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    5/29/26 6:28:50 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Demski Martha J

    4 - Equillium, Inc. (0001746466) (Issuer)

    5/29/26 6:27:09 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pruzanski Mark

    4 - Equillium, Inc. (0001746466) (Issuer)

    5/29/26 6:25:11 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $3.08, Equ

    6/2/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

    LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.

    5/28/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

    LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a virtual investor event on Wednesday, May 27, 2026, at 11:00 AM ET. The event will be presented by Stephen Connelly Ph.D., Equillium's Chief Scientific Officer, and include new preclinical data evaluating several clinically relevant AhR modulators and further characterization of the relationship between AhR activation and miR-124 induction in both immune and epithelial cells. AhR is a xenosensor essential for maintaining intestinal barrier function and immune homeostasis an

    5/20/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    SEC Filings

    View All

    SEC Form 8-K filed by Equillium Inc.

    8-K - Equillium, Inc. (0001746466) (Filer)

    5/29/26 4:05:29 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Equillium Inc.

    10-Q - Equillium, Inc. (0001746466) (Filer)

    5/13/26 4:10:34 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Equillium, Inc. (0001746466) (Filer)

    5/13/26 4:05:19 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Equillium upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Equillium from Market Perform to Outperform and set a new price target of $6.00

    5/28/26 8:44:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Equillium with a new price target

    Oppenheimer initiated coverage of Equillium with a rating of Outperform and set a new price target of $7.00

    4/23/26 7:55:51 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Equillium with a new price target

    B. Riley Securities initiated coverage of Equillium with a rating of Buy and set a new price target of $6.00

    4/16/26 9:01:30 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Leadership Updates

    Live Leadership Updates

    View All

    Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

    Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy Cash and cash equivalents expected to fund currently planned operations into 2029 LA JOLLA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update hi

    5/13/26 4:01:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to be included in the Russell Microcap® Index

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va

    6/12/24 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Equillium Inc.

    SC 13G - Equillium, Inc. (0001746466) (Subject)

    1/19/24 6:03:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    3/3/23 9:27:36 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Financials

    Live finance-specific insights

    View All

    Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

    Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

    3/27/25 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Maintains Rights to Itolizumab Following Ono Partnership

    Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

    10/31/24 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

    Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

    12/6/22 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care